We are proud to announce Patent Pending status of our novel approach to preventing Clostridioides difficile infection using egg-derived polyclonal antibodies. This innovative technology represents a significant advancement in the fight against C. difficile, a major cause of healthcare-associated infections worldwide.

Our research team has developed a proprietary method for producing highly effective antibodies that target various components causing C. difficile infection, offering a promising preventive strategy for at-risk populations.